

ASSTON PHARMACEUTICALS PRIVATE LIMITED

CIN: - U24304MH2019PTC324187 Reg. Office- OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India, Phone No.: 022-49731419 / 49731411, Email ID: - aston.tech14@gmail.com,

NOTICE OF THE ANNUAL GENERAL MEETING

NOTICE BE AND IS HEREBY GIVEN THAT AN ANNUAL GENERAL MEETING ("AGM") OF THE SHAREHOLDERS OF ASSTON PHARMACEUTICAL PRIVATE LIMITED ON THURSDAY, DECEMBER 31ST 2020, AT 11:00 A.M. AT REGISTERED OFFICE OF THE COMPANY AT OFFICE NO B-225, BALAJI BHAVAN, PLOT NO 42A SECTOR-11 CBD BELAPUR NAVI MUNBAI THANE 400614 TO TRANSACT THE FOLLOWING BUSINESSES:

ORDINARY BUSINESS:

ITEM NO:-01

TO RECEIVE, CONSIDER AND ADOPT THE BALANCE SHEET STANDALONE AND CONSOLIDATED AS AT MARCH 31, 2020 AND PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED ON THAT DATE AND THE REPORT OF DIRECTORS AND AUDITORS THEREON.

"RESOLVED THAT the Standalone and consolidated Audited Statements of the Company for the Financial Year ended March 31, 2020, and the Reports of Directors and Auditors thereon for the financial year ended March 31, 2020, be and are hereby adopted"

ITEM NO -02

TO APPOINTMENT OF M/S POOJA V. RAVANI & CO. TILL THE CONCLUSION OF THE SIXTH ANNUAL GENERAL MEETING

"RESOLVED THAT M/s POOJA V. RAVANI & CO. Chartered Accountants registered with Institute of Chartered Accountant Of India vide registration no. 140450W having submitted the written certificate pursuant to the provisions to the section 139(1) of the companies act, 2013, be and is hereby appointed as Statutory Auditors of the company to hold office from the conclusion of the First Annual General Meeting of the company till the Conclusion of the Sixth Annual General Meeting of the company to be held in the financial year 2025, on the remuneration as fixed by the director of the company in addition of the out of pocket expenses to be incurred by them in connection with the audit"

FOR ASSTON PHARMACEUTICAL PRIVATE LIMITED


ASHISH NARAYAN SAKALKAR

DIRECTOR

DIN: -06601011

Date: - 10/12/2020

Place: - Mumbai



ASSTON PHARMACEUTICALS PRIVATE LIMITED

CIN: - U24304MH2019PTC324187 Reg. Office- OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India, Phone No.: 022-49731419 / 49731411, Email ID: - aston.tech14@gmail.com,

NOTES: -

1. AN EQUITY SHAREHOLDER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND SUCH PROXY NEED NOT BE AN EQUITY SHAREHOLDER OF THE COMPANY. THE INSTRUMENT APPOINTING PROXY, IN ORDER TO BE EFFECTIVE MUST BE LODGED WITH THE REGISTERED OFFICE OF THE COMPANY NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING. A PROXY FORM IS ENCLOSED.
2. EQUITY SHAREHOLDERS/PROXIES ATTENDING THE MEETING ARE REQUESTED TO BRING THEIR COPY OF EGM NOTICE TO THE MEETING AND ATTENDANCE SLIP DULY SIGNED SO AS TO AVOID INCONVENIENCE.
3. EQUITY SHAREHOLDERS ARE REQUESTED TO INTIMATE THE CHANGE(S), IF ANY OF THE ADDRESSES WITH THE COMPANY AT THE EARLIEST.
4. CORPORATE EQUITY SHAREHOLDER(S) INTENDING TO SEND THEIR AUTHORIZED REPRESENTATIVE ARE REQUESTED TO SEND A DULY CERTIFIED COPY OF THE BOARD RESOLUTION AUTHORIZING THEIR REPRESENTATIVE(S) TO ATTEND AND VOTE AT THE EXTRAORDINARY GENERAL MEETING.
5. BOARD RESOLUTIONS AUTHORIZING REPRESENTATIVES OF CORPORATE SHAREHOLDERS SHOULD BE SENT BEFORE THE MEETING.
6. THE EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) AND SECTION 68(3) OF THE COMPANIES ACT, 2013 IN RESPECT OF SPECIAL BUSINESS TO BE TRANSACTED AT THE MEETING IS ANNEXED HERETO.
7. ALL DOCUMENTS REFERRED TO IN THE ACCOMPANYING NOTICE AND EXPLANATORY STATEMENT ARE OPEN FOR INSPECTION AT THE REGISTERED OFFICE OF THE COMPANY BETWEEN 11:00 HOURS AND 16:00 HOURS ON ANY WORKING DAY PRIOR TO THE DATE OF THE MEETING AND WILL ALSO BE AVAILABLE ON THE DATE OF THE MEETING (EXCEPT SATURDAY AND PUBLIC HOLIDAYS).

ASSTON PHARMACEUTICALS PRIVATE LIMITED

CIN: - U24304MH2019PTC324187 Reg. Office- OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A,
SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India, Phone No.: 022-49731419 /
49731411, Email ID: - aston.tech14@gmail.com,

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013:

No explanatory Statement required with the notice as all the agenda items are ordinary business.

ASSTON PHARMACEUTICALS PRIVATE LIMITED

CIN: - U24304MH2019PTC324187 Reg. Office- OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India, Phone No.: 022-49731419 / 49731411, Email ID: - aston.tech14@gmail.com,

ATTENDANCE SLIP EXTRA ORDINARY GENERAL MEETING

CIN: U24304MH2019PTC324187

Name of the Company: ASSTON PHARMACEUTICALS PRIVATE LIMITED

Registered Office: OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India.

ATTENDANCE SLIP

Registered Folio/DP ID & Client ID	
Name	
Address of Shareholder	

I/We hereby record my/our presence at Extra Ordinary General Meeting of the Company on Thursday, the 31ST December, 2020 at 11.00 A.M at the Registered office of the Company at OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India.

Signature of Shareholder/Proxy

I record my presence at the Extraordinary General Meeting

(Signature of Member/Proxy)

Name of Proxy in block letters
(If proxy attends instead of the member)

ASSTON PHARMACEUTICALS PRIVATE LIMITED

CIN: - U24304MH2019PTC324187 Reg. Office- OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India, Phone No.: 022-49731419 / 49731411, Email ID: - aston.tech14@gmail.com,

Form No. MGT-11 (Proxy Form)

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U24304MH2019PTC324187

Name of the Company: ASSTON PHARMACEUTICALS PRIVATE LIMITED

Registered Office: OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India.

Name of the Member(s):

Registered address:

E-mail Id:

Folio No./Client Id & DP. Id:

I/We, being the Member(s) of _____ shares of the above-named Company, hereby appoint

Name:.....

Address:

E-mail Id:

Signature:..... ,

or failing him

Name:.....

Address:

E-mail Id:

Signature:,

and whose signature(s) are appended below as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Extra Ordinary General Meeting of the Company on Thursday, the 31st December, 2020 at 11.00 A.M at the Registered office of the Company at OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India.

and at any adjournment thereof in respect of such resolutions.

Signed this _____ day of _____ 2020.

Signature of Shareholder(s):

Signature of Proxy holder(s):

Affix Reven
Stamp

ASSTON PHARMACEUTICALS PRIVATE LIMITED

CIN: - U24304MH2019PTC324187 Reg. Office- OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane Maharashtra 400614 India, Phone No.: 022-49731419 / 49731411, Email ID: - aston.tech14@gmail.com,


Notes:


This form of proxy in order to be effective should be duly completed and deposited at the Corporate Office of the Company, not less than 48 hours before the commencement of the Meeting. A proxy need not be a member of the Company.

For the resolutions and Notes, please refer to the Notice of the Annual General Meeting.

Appointing a proxy does not prevent a member from attending the meeting in person if he/she so wishes.

ROUTE MAP





ASSTON PHARMACEUTICALS PVT.LTD. (F.Y.2019-20)

INDEPENDENT AUDITORS REPORT

**To the Members of ASSTON PHARMACEUTICALS PVT.LTD.
Report on the Audit of the Financial Statements**

Opinion

1. We have audited the accompanying financial statements of **ASSTON PHARMACEUTICALS PVT.LTD.** ("the Company"), which comprise the Balance Sheet as at **March 31, 2020**, and the Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, and its profit for the year ended on that date.

Basis of Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

4. Management has assessed the potential impact of COVID 19 based on the current circumstances and expect no significant impact on the continuity of operations of the





ASSTON PHARMACEUTICALS PVT.LTD. (F.Y.2019-20)

business on the long term basis/ on the useful life of the assets/on financial position etc. though there may be lower revenues.
Our Opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

5. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance of the company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.





ASSTON PHARMACEUTICALS PVT.LTD. (F.Y.2019-20)


Auditor's Responsibility for audit of Financial Statement

6. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





ASSTON PHARMACEUTICALS PVT.LTD. (F.Y.2019-20)

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

7. The provisions of the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is not applicable to the Company since


(a) It is not a subsidiary or holding company of a public company;

(b) Its paid-up capital and reserves and surplus are not more than Rs.1 Crores as at the balance sheet date;

(c) Its total borrowings from banks and financial institutions are not more than Rs.1 Crores at any time during the year; and


(d) Its turnover for the year is not more than Rs.10 Crores during the year.





ASSTON PHARMACEUTICALS PVT.LTD. (F.Y.2019-20)

8. As required by Section 143 (3) of the Act, we report that:
- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss, dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on **March 31, 2020** taken on record by the Board of Directors, none of the directors are disqualified as on **March 31, 2020** from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:





ASSTON PHARMACEUTICALS PVT.LTD. (F.Y.2019-20)

- i. The Company does not have any pending litigations which would impact its financial position.
- ii. The Company does not have any long-term contracts including derivative contracts outstanding as on March 31, 2020 for which there were any material foreseeable losses.
- iii. There were no amounts required to be transferred, to the Investor Education and Protection Fund by the Company.

For POOJA V. RAVANI & CO.

Chartered Accountants
FRN: 140450W

P.V. Ravani



C. A. POOJA v. ravani

(Proprietor)

Mem.No:163629

UDIN: :21163629AAAAAX5524

Place : Dombivli

Date : 10/12/2020

ASSTON PHARMACEUTICALS PVT. LTD.
BALANCE SHEET AS AT 31ST MARCH 2020

Sr no	Particulars	Note No.	Figures as at the end of the current reporting period as on 31.03.20	Figures as at the end of the Previous reporting period
	1	2	3	4
I.	EQUITY AND LIABILITIES			
(1)	Shareholders' Funds			
	(a) Share Capital	1	1,00,000.00	-
	(b) Reserves and Surplus	2	3,51,760.47	-
	(c) Money received against share warrants		-	-
(2)	Share Application Money Pending allotment			
(3)	Non - Current Liabilities			
	(a) Long Term Borrowings	3	75,30,299.00	-
	(b) Deferred Tax Liabilities (Net)		-	-
	(c) Other Long Term Liabilities	4	25,45,962.00	-
	(d) Long - Term Provisions		-	-
(4)	Current Liabilities			
	(a) Short Term Borrowings			
	(b) Trade Payables		1,05,36,114.37	-
	(c) Other Current Liabilities	5	54,375.00	-
	(d) Short - Term Provisions	6	4,35,480.00	-
	TOTAL		2,15,53,990.84	-
II.	ASSETS			
(1)	Non - Current Assets			
	(a) Fixed Assets			
	(i) Tangible Assets	7	87,912.00	-
	(ii) Intangible Assets		-	-
	(iii) Capital Work-in-Progress		-	-
	(iv) Intangible Assets under Development		-	-
	(b) Non - Current Investments		-	-
	(c) Deferred Tax Assets (Net)		-	-
	(d) Long - Term Loan and Advances	8	2,00,000.00	-
	(e) Other Non - Current Assets			
(2)	Current Assets			
	(a) Current Investments		-	-
	(b) Inventories		59,58,474.00	-
	(c) Trade Receivables	9	95,69,636.76	-
	(d) Cash and Cash Equivalents		41,45,173.18	-
	(e) Short Term Loans and Advances	10	13,15,794.90	-
	(f) Other Current Assets	11	2,77,000.00	-
	TOTAL		2,15,53,990.84	-
III.	NOTES FORMING PART OF THE FINANCIAL STATEMENTS			

The accompanying notes forms an integral part of financial statements.
As per our report of even date attached.



FOR POOJA V. RAVANI & CO.
CHARTERED ACCOUNTANTS

P.V. Ravani
POOJA V. RAVANI
(PROPRIETOR)
MEMBERSHIP NO. 163629
FRN : 140450W

Date: 10/12/2020



FOR ASSTON PHARMACEUTICALS PVT. LTD.

H. Sekani
smell
Director

UDIN :- 21163629 AAAAW 9572

ASSTON PHARMACEUTICALS PVT. LTD
PROFIT & LOSS STATEMENT
FOR THE YEAR ENDED 31ST MARCH, 2020

Sr no	Particulars	Note No.	Figures as at the end of the current reporting period as on 31.03.20	Figures as at the end of the Previous reporting period
I.	Revenue from Operations		2,49,81,729.40	-
II.	Other Income	12	2,51,937.28	-
III.	Total Revenue (I + II)		2,52,33,666.68	-
IV.	Expenses :			
a)	Cost of Materials Consumed		-	-
b)	Purchases of stock-in-trade		2,34,48,244.48	-
c)	Changes in Inventories of Finished Goods Work-in-Progress and stock-in-trade	13	(59,58,474.00)	-
d)	Employee Benefits Expense	14	18,27,210.00	-
e)	Finance Costs	15	1,79,360.18	-
f)	Depreciation and Amortization Expense		7,588.00	-
g)	Other Expense	16	53,77,977.55	-
	Total Expenses		2,48,81,906.21	-
V.	Loss Before Exceptional and Extraordinary Items and Tax (III - IV)		3,51,760.47	-
VI.	Exceptional Items		0.00	
VI.	Profit Before Extraordinary Items and Tax (V- VI)		3,51,760.47	-
VII.	Extraordinary Items			
VIII.	Profit Before Tax (VII - VIII)		3,51,760.47	-
IX.	Tax Expenses :			
	(1) Current Tax		-	
	(2) Deferred Tax		-	
X.	Profit/ (Loss) for the period from continuing operations.		-	-
XI.	Profit/(Loss) for the period		3,51,760.47	-
XII.	Earnings per equity share :			
	(1) Basic		35.176	-
	(2) Diluted			
XIII.	NOTES FORMING PART OF THE FINANCIAL STATEMENTS			

The accompanying notes forms an integral part of financial statements.
As per our report of even date attached.

FOR POOJA V. RAVANI & CO.
CHARTERED ACCOUNTANTS

FOR ASSTON PHARMACEUTICALS PVT. LTD.



PV Ravani
POOJA V. RAVANI
(PROPRIETOR)
MEMBERSHIP NO. 163629
FRN : 140450W



Smoll
Director

Date: 10/12/2020

UDIN= 21163629AAAAAW9572

NOTE 1

Note of Share Capital annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.20	31.03.19
1) Authorised Capital 100,000 Equity shares of Rs. 10/- each	10,00,000.00	-
2) Issued, Subscribed and paid up 10,000 Equity shares of RS.10/- each fully paid	1,00,000.00	-
TOTAL	1,00,000.00	-

Reconciliation of Number of Shares and Amount outstanding at the beginning and at end of the reporting period :

Particulars	Opening Balance	Fresh Issue	BuyBack	Closing Balance
Equity shares with voting rights				
Year Ended 31st March 2020				
: Number of Shares	10000	-	-	10000
: Amount (Rs.)	1,00,000.00	-	-	1,00,000.00
Year Ended 31st March 2019				
: Number of Shares	0	-	-	0
: Amount (Rs.)	-	-	-	-

Details of Shares held by each Shareholder holding more than 5% shares :

Classes of shares/ Name of Shareholders	As at 31st March 2020		As at 31st March 2019	
	No of Shares held	% of Shares held	No of Shares held	% of Shares held
Equity Shares				
Ashish Sakalkar	5,000.00	50.00%	-	0.00%
Saill More	5,000.00	50.00%	-	0.00%
	10,000.00	100.00%		0.00%

NOTE 2

Note of Reserves & Surplus annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	As at 31/3/2020 (Rs.)	As at 31/3/2019 (Rs.)
(a) Share Premium		
Opening Balance		
: Additions during the year		
: Utilised/Transferred during the year		
Closing Balance		
(b) General Reserve		
Opening Balance	-	-
: Additions during the year	-	-
: Transitional effect as per Schedule II	-	-
: Utilised/Transferred during the year	-	-
Closing Balance	-	-
(c) Profit and Loss A/c		
Opening Balance	-	-
: Additions during the year	3,51,760.47	-
: Utilised/Transferred during the year	-	-
Closing Balance	3,51,760.47	-
(d) Capital reserve		
Opening Balance	-	-
: Additions during the year	-	-
: Utilised/Transferred during the year	-	-
Closing Balance	-	-
TOTAL	3,51,760.47	-



Small
Harkaus

NOTE 3

Note of Long term Borrowings annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
Loan From Bank Of Maharashtra	75,30,299.00	
TOTAL	75,30,299.00	-

NOTE 4

Note of Other Long term Borrowings annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
Loan From Asston International	25,45,962.00	
TOTAL	25,45,962.00	-

NOTE 5

Note of Other Current Liabilites annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
Statutory Paybles	54,375.00	
TOTAL	54,375.00	-

NOTE 6

Note of Provisions annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
SALARY PAYABLE	4,35,480.00	
TOTAL	4,35,480.00	-

small
H. Bakshi



NOTE 7 OF FIXED ASSETS AND DEPRECIATION UNDER COMPANIES ACT, 2013 AS ON 31.03.2020

DESCRIPTION	Cost as at 01.04.19	Additions during the year	Cost as at 31.03.2020	Depreciation Provided during the year	Total upto 31.03.2020	NET BLOCK W.D.V. as at 31.03.2020
TANGIBLE FIXED ASSET						
Fixture & Furniture		28,000.00	28,000.00	1,251.00	1,251.00	26,749.00
Computer & Accessories		67,500.00	67,500.00	6,337.00	6,337.00	61,163.00
TOTAL	-	95,500.00	95,500.00	7,588.00	7,588.00	87,912.00

H. Sakam
SMU



NOTE 8

Note of Long Term Loans & Advances annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
<u>Deposits :</u>		
RENT DEPOSIT	2,00,000.00	
	-	
	2,00,000.00	-

NOTE 9

Note of Trade Receivables annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
1) Sundry Debtors For Goods (O/s Less than six months)	95,69,636.76	
a. Secured Considered Good		
b. Unsecured Considered Good	-	-
c. Considered Doubtful		
TOTAL	95,69,636.76	-

NOTE 10

Note of Short Term Loans & Advances annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
<u>Loans & Advances</u>		
Tax For 2019-20	75,000.00	-
GST BALANCE	12,40,794.90	
	13,15,794.90	-

NOTE 11

Note of Other Current Assets annexed to & forming part of Balance Sheet as at 31.03.2020

Particulars	31.03.2020	31.3.2019
Other Current Asset	2,77,000.00	
	2,77,000.00	-

Smal
H. Sakar



NOTE 12

**Note of Other Income annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2020**

Particulars	31.03.2020	31.03.2019
Export Incentives	2,29,036.00	-
Discount Received	6,600.00	-
Other Income	16,301.28	-
TOTAL	2,51,937.28	-

NOTE 13

**Note of details of Stock of Finished Goods & Consumables annexed to &
forming part of Profit & Loss Account for the year ended on 31.03.2020**

Particulars	31.03.20	31.03.19
Stock of Finished Goods & Consumables at the beginning of the Period	-	-
Stock of Finished Goods & Consumables at the end of the Period	59,58,474.00	-
Total	(59,58,474.00)	-

NOTE 14

**Note of Employee Benefits Expenses annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2020**

Particulars	31.03.20	31.03.19
Directors Remuneration	14,00,000.00	-
Salary	4,27,210.00	-
Total	18,27,210.00	-

Smol
H. Akalya



NOTE 15

Note of Finance Expenditure annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2020

Particulars	31.03.2020	31.03.2019
Bank Charges	50,224.18	-
Bank Interest	1,29,136.00	-
	1,79,360.18	-

NOTE 16

Note of Other Expenditure annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2020

Particulars	31.03.2020	31.03.2019
Clearing & Forwarding Charges	17,02,321.89	
Courier Charges	68,025.67	
Computer & Software Expenses	3,600.00	
Electricity Charges	32,640.00	
Freight & Forwarding Charges	59,978.00	
Ful & Petrol Expenses	15,500.00	
Inspection Charges	10,000.00	
Interest on PT	975.00	
Interest on TDS	3,304.00	
Labour Charges	25,22,864.00	
Licenses Fees	5,250.00	
Misc Expenses	6,562.43	
Office Expenses	73,500.00	
Office Rent	3,60,000.00	
Packing & Forawrding Charges	380.00	
Printing & Stationery	24,704.00	
Processing Fees	26,250.00	
Professional Fees	33,500.00	
Roc Expenses	22,400.00	
Refreshment Expenses	17,440.00	
Travelling Expenses	69,754.00	
Telephone Expenses	12,898.56	
Testing Charges	1,37,820.00	
Transport Charges	1,68,310.00	
Total	53,77,977.55	-

Smol
H. K. K. K.



ASSTON PHARMACEUTICALS PVT. LTD.

CASH FLOW STATEMENT (AS-3) FOR THE YEAR ENDED 31.03.2020

Particulars	Note	Rs	Rs
NET PROFIT BEFORE TAXATION	2		351760.47
<u>Add Back:</u>			
Depreciation on Fixed Assets	7	7588.00	136724
Interest Paid	15	129136.00	488484.47
CASH GENERATED BEFORE WORKING CAPITAL CHANGES			
CHANGE DUE TO WORKING CAPITAL			
Add:			
Increase in Creditors		1,05,36,114.37	11025969.37
Increase in Outstanding Expenses	5 & 6	4,89,855.00	
Less :			
Increase in Debtors	9	95,69,636.76	
Increase in Stock		59,58,474.00	
Increase in Other Current Asset	10	13,15,794.90	16843905.66
CASH GENERATED FROM OPERATIONS			(53,29,451.82)
A NET CASH FLOW FROM OPERATING ACTIVITIES			
Purchase of Fixed Assets	7	95500.00	
Deposit for Rental Premises	8	2,00,000.00	(2,95,500.00)
B NET CASH FLOW FROM INVESTING ACTIVITIES			
Proceeds from Issue of Shares including premium	1	1,00,000.00	
Proceeds from Bank of Maharashtra	3	75,30,299.00	
Unsecured Loan	4-11	22,68,962.00	
Interest Paid	15	-129136.00	9770125.00
C NET CASH FLOW FROM FINANCING ACTIVITIES			97,70,125.00
NET CASH & CASH EQUIVALENTS FOR F.Y YEAR ENDED 31.03.2020 (A+B+C)			41,45,173.18

FOR POOJA V. RAVANI & CO.
CHARTERED ACCOUNTANTS

P V Ravani

POOJA V. RAVANI
(PROPRIETOR)
MEMBERSHIP NO. 163629
FRN : 140450W
Date : 10/12/2020

FOR ASSTON PHARMACEUTICALS PVT. LTD.

H. S. S. S. S.
Director



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year: 2019-2020)

NOTES ON ACCOUNTS & ACCOUNTING POLICIES

1. A) SIGNIFICANT ACCOUNTING POLICIES

A) Basis for preparation of Financial Statements (AS 1)

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013.

The financial statements have been prepared under the historical cost convention on accrual basis.

B) Inventories (AS 2):

Inventories are valued at lower of cost or Net realizable value. Cost is computed on the basis of cost of purchase under "Fist-In- First-Out" basis.

C) Contingencies & Events Occurring After B/S Date (AS 4)

No Significant Events as mentioned in AS-4 occurred between the balance sheet date and the date of Approval of Financial Statements, which had a significant Effect on the Financial Statement.

D) Prior Period Items& Change in Accounting Policies (AS 5)

During the year, there were no transactions relating to the prior period which require a separate disclosure and there was no material change in the accounting policies, which requires a separate disclosure since its first years of operation.

E) Depreciation (AS 6)

Depreciation has been provided on the Fixed Assets, on WDV basis in accordance with the companies Act, 2013 at the rates specified in schedule II of the Companies Act, 2013.



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year 2019-2020)

F) Income Recognition (AS 9)

Revenue from Export sales, including export incentives, are recorded on the occurrence of sale. Income in the form of discounts & other credits allowed by the supplier company are recorded when the supplier company allows it by issuing a credit note/other relevant document.

G) Fixed Assets (AS 10)

Fixed Assets are stated at Cost less accumulated depreciation.

H) Investments (AS 13)

There are no investments made by the company

I) Employee Benefits (AS 15)

The company has neither quantified nor provided for retirement benefits, since first year of its operation.

J) Borrowing Cost (AS 16)

During the year company has not acquired any qualifying Asset from borrowed funds. No borrowing cost is incurred by the company during the year.

K) Related Party Disclosure (AS 18)

In pursuant to disclosure requirement as prescribed under the Accounting Standard (AS-18) 'Related Party Disclosure' issued by the Council of the Institute of Chartered Accountants of India, following disclosure is made in respect of the transactions with the related party.

Name of the Related Party	Nature of Relation	Nature of transaction	Amount
Ashish Sakalkar	Director	Director's Remuneration	Rs. 7,00,000/-
Saili More	Director	Director's Remuneration	Rs. 7,00,000/-
TOTAL			Rs. 14,00,000/-



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year 2019-2020)

L) Earning Per Share (AS 20)

	2019-20	2018-19
Net Profit/(Loss) for the year	3,51,760/-	
No. of Shares	10,000	
Earning Per Share	35.176/-	

M) Impairment of Assets (AS28)

During the year no asset is impaired as mentioned in AS 28 and hence question of transferring loss to Profit & Loss Account as required by AS 28 does not arise.

N) Cash Flow Statement (AS-3):

Cash Flow Statement is prepared as per AS-3 issued by ICAI

O) Taxation


Company has exercised option to avail concessional rate of tax @ 22% under Section 115BAA of Income Tax Act, under new scheme of taxation.

P) Provisions, Contingent Liabilities and Contingent Assets (AS 29)

Contingent liabilities and contingent assets are neither recognised nor disclosed in the financial statement. Further as on 31st March, 2020 there are no contingent liabilities which should have been disclosed in the financial statements.


FOR ASSTON PHARMACEUTICALS PVT. LTD.

POOJA V. RAVANI & CO.
Chartered Accountants
Firm Reg.No.140450W


Director



Date: 10/12/2020
Place: Dombivli


(Proprietor)
M. No. 163629



Directors' Report to the Shareholders:

Your Directors present their 1st Report together with the Audited Financial Statements of your Company for the period ended 31st March, 2020.

1. Financial Highlights and State of Company's Affairs:

PARTICULARS	Period Ended 31 st March 2020 (In Rs)
Total Revenue	2,52,33,666.68
Profit / (Loss) before taxation	3,51,760.47
Less: Tax Expenses	-
Profit/Loss after tax	3,51,760.47

No material changes and commitments affecting the financial position of the Company have occurred after the closure of the financial year to which these financial statements relate and the date of this report.

2. Operations

The company's revenue for the year ended 31st March, 2020 was Rs. 2,52,33,666.68/- and profit of Rs. 3,51,760.47/- Company does not have any subsidiaries, Associates or Joint Ventures.

3. Dividend

Your Directors do not recommend any dividend on equity shares for the year. Your Directors have not paid any interim Dividend during the year. There is no unpaid Dividend of earlier years which has been transferred or due to be transferred to Investor Education and Protection Fund during the year.

4. Share Capital

The Authorized Share Capital of your Company as on 31st March, 2020 stood at Rs.10,00,000. Accordingly, as on 31st March, 2020, the paid-up share capital of your Company stood at Rs. 1 Lakh.



5. BOARD OF DIRECTORS

Composition:

Presently, the Board comprises of the following Four Directors:

Name of the Director	DIN	Designation
SAILI JAYARAM MORE	02691527	DIRECTOR
ASHISH NARAYAN SAKALKAR	06601011	DIRECTOR

All Directors of your Company have given requisite declaration pursuant to Section 164 of the Companies Act, 2013 that they are not disqualified to be appointed as Directors.

Your Company is not required to constitute any mandatory committees of the Board.

Provisions relating to annual evaluation of Board, Committees and individual Directors are not applicable to your Company.

6. Board meeting

During the financial year under review 6 (Six) meetings of Board of Directors were convened and held. The intervening gap between the meetings was within the period prescribed under the Companies Act, 2013.

7. Compliance with Secretarial Standards

The Directors have devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards and that such systems are adequate and operating effectively.

8. Directors' Responsibility Statement

Pursuant to section 134(3)(c) of the Companies Act, 2013, your Directors, based on representation from operating management and after due enquiry, confirm that:

- (i) In the preparation of the annual accounts, the applicable accounting standards have been followed and there have been no departures;
- (ii) Accounting policies have been selected in consultation with the Statutory Auditors and these have been applied consistently and reasonable and prudent judgments and estimates have been made so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2020 and of the Profit of the Company for the year ended on that date;
- (iii) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;



- (iv) The annual accounts have been prepared on a going concern basis;
- (v) The Company has laid down internal financial controls. The Company has also assessed the adequacy of the Company's internal controls over financial reporting as of 31st March, 2020 and have found them to be adequate and
- (vi) Proper systems have been devised to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

9. CORPORATE SOCIAL RESPONSIBILITY

Provision relating to corporate social responsibility (CSR) enumerated under section 135 of the Companies Act 2013 are not applicable.

10. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

During the year, no company has become/ ceased to be a subsidiary or an associate or joint venture company of the Company. Therefore, the requirements of consolidated financial statement are not applicable to the Company.

11. Statutory Auditors

M/s. POOJA V. RAVANI & CO Chartered Accountant (Firm Reg No. 140450W) were appointed as First auditors of the company to hold office till the conclusion of 1ST AGM.

In the ensuing AGM, M/s. POOJA V. RAVANI & CO Chartered Accountant (Firm Reg No. 140450W) is appointed as Statutory Auditor of the Company for a term of 5 years starting from the conclusion this Annual General Meeting till the conclusion of 6THAGM to be held on 2025.

The Company has obtained a certificate from the Auditor, confirming that their appointment, if any, would be in accordance with the conditions prescribed under the Act and that they satisfy the criteria provided in section 141.

The Auditors Report for the year ended 31st March, 2020, does not contain any qualification, reservation or adverse remark.

12. Reporting of frauds by Auditors

During the year under review, the Statutory Auditors have not reported any instance of frauds committed in the Company as per Section 143 (12) of the Companies Act, 2013, details of which needs to be mentioned in the Report.

13. Secretarial Auditor, Cost Auditor and Internal Auditor

During the year under review, the provisions relating to Secretarial Auditor, Cost Auditor and Internal Auditor were not applicable to your Company.



14. Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

The particulars relating to the Energy Conservation, Technology Absorption and Foreign Exchange Earnings and Outgo, as required under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 (3) of The Companies (Accounts) Rules, 2014 are as follows:

a. Conservation of energy & Technology absorption

As the Company is providing services in logistics sector, particular required to be disclosed with respect to the conservation of energy in terms of Section 134(3) of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014. It is the policy of the management to keep abreast of technological developments in the field in which the company is operating and to ensure that the Company uses the most suitable technology. During the year, the Company did not adopt any innovative technologies. Following are the details of Energy Consumption.

Particulars	31.03.2020
Electricity Consumption (in Rs)	32,640

b. Foreign exchange earnings and Outgo

During the year review, following are details of foreign exchanges.

Particulars	FY 2018-19
Foreign Exchange Earnings (In Rs)	2,49,81,729.40
Foreign Exchange Outgo (In Rs)	NIL

15. Particulars of Public Deposits, Loans, Guarantees or Investments

Your Company has not accepted any deposits from the public during the year under review. There were no deposits which are not in compliance with the requirements of Chapter V of Companies Act, 2013.

The Company has not granted any loans, provided any securities and not made any investments pursuant to Section 186 of the Companies Act, 2013 during the year under review.

16. Extract of Annual Return

Pursuant to Section 92(3) of the Companies Act, 2013 read with Rule 12(1) of the Companies 17. (Management and Administration) Rules, 2014, an extract of the Annual return as on 31st March, 2020 is attached herewith as *Annexure I* and forms part of this report.

17. Particulars of Transactions with Related Parties

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of the business. There are no materially significant related



party transactions made by the company with Promoters, Key Managerial Personnel or other designated persons which may have potential conflict with interest of the company at large, and hence, the requirement of Form AOC-2 are not applicable for the year under review.

18. OTHER DISCLOSURES

- A. No penalties/strictures were imposed on the Company by any statutory authority on any matter. There were no significant and material orders passed by regulators or courts or tribunals impacting the going concern status & Company's operations in future
- B. The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. Based on the report of internal audit function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant audit observations and recommendations, if any, along with corrective actions thereon are presented to the Audit Committee of the Board.
- C. There is no occurrence of any material changes and/ or commitment affecting the financial position of the company between the end of the financial year to which this financial statements relate and the date of the report.
- D. During the year under review no revision was made in the financial statement of the Company.
- E. The Company has in place the mechanism for Risk Assessment. The Board by way of periodical review ensures that risk, if any, is controlled and managed by means of properly designed framework.
- F. The provisions of maintenance of cost records under Section 148 (1) of the Companies Act, 2013 are not applicable to the Company.
- G. The Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company has an internal HR policy dealing with Sexual Harassment. The Company has not received any complaint of sexual harassment during the year under review.
- H. To ensure the safety of its employees and to combat the COVID-19 pandemic in compliance with the directives of the Central as well as State Government, the Company had shut operations with effect from March 22, 2020. The country-wide lock since then has resulted in significant disruptions in business operations. The Company resumed operations in phased manner as per government guidelines.



19. Acknowledgements

Your Directors are pleased to take this opportunity to thank the Bankers, Customers, Vendors and all the other Stakeholders for their co-operation to the Company during the year under review.

For and on behalf of the Board of
ASSTON PHARMACEUTICALS PRIVATE LIMITED



SAILI MORE
DIRECTOR
DIN: 02691527



ASHISH SAKALKAR
DIRECTOR
DIN: 06601011



Date: 10th December, 2020

ANNEXURE I TO BOARD'S REPORT

Form No. MGT-9

EXTRACT OF ANNUAL RETURN

As on the financial year ended on 31st March, 2020.

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS :

a)	CIN	U24304MH2019PTC324187
b)	Registration Date	16/04/2019
c)	Name of the Company	ASSTON PHARMACEUTICALS PRIVATE LIMITED
d)	Category/Sub-Category of the Company	Company limited by shares/Indian Non-Government company
e)	Address of the registered office and contact details	OFFICE NO. B-225, BALAJI BHAVAN, PLOT NO 42A, SECTOR-11, CBD BELAPUR, NAVI MUMBAI Thane MH 400614 IN
f)	Whether listed Company	UNLISTED
g)	Name, Address and Contact Details of Registrar and Transfer agent, if any	NA

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the Company shall be stated: -

Sr. No.	Name and Description of main products/services	NIC Code of the Product/Service	% to total turnover of the company
1.	The Company is primarily engaged in the manufacture and export of packaged ORS and other pharmaceutical products.	210	100%



III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S. No.	Name and Address of the Company	CIN/GLN	HOLDING/ SUBSIDIARY/ ASSOCIATE	% of share held	Applicable section
1.	NA	NA			

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Holding

Category of Shareholders	No. Of shares held at the beginning of the year (as on incorporation date)				No. Of shares at the end of the year				% Change during year
	Demat	Physical	Total	% of Total shares	Demat	Physical	Total	% of Total Shares	
A. Promoter									
(1) Indian									
a) Individual/HUF	0	10000	10000	100	0	10000	10000	100	0
b) Central Govt.	0	0	0	0	0	0	0	0	0
c) State Govt.(s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	0	0	0	0	0	0	0	0
e) Banks/ FI	0	0	0	0	0	0	0	0	0
f) Any Other...	0	0	0	0	0	0	0	0	0
Sub Total(A) (1):-	0	10000	10000	100	0	10000	10000	100	0
(2) Foreign									
a) NRIs- Individuals	0	0	0	0	0	0	0	0	0
b) Other- Individuals	0	0	0	0	0	0	0	0	0



c) Bodies Corp.	0	0	0	0	0	0	0	0	0
d) Banks/ FI	0	0	0	0	0	0	0	0	0
e) Any Other...	0	0	0	0	0	0	0	0	0
Sub-Total(A)(2):	0	0	0	0	0	0	0	0	0
Total shareholding of Promoter (A)= (A)(1)+(A)(2)	0	10000	10000	100	0	10000	10000	100	0
B. Public Shareholding									
1) Institutions									
a) Mutual Funds / UTI	0	0	0	0	0	0	0	0	0
b) Banks / FI	0	0	0	0	0	0	0	0	0
c) Central Govt.	0	0	0	0	0	0	0	0	0
d) State Govt.(s)	0	0	0	0	0	0	0	0	0
e) Venture Capital Funds	0	0	0	0	0	0	0	0	0
f) Insurance Companies	0	0	0	0	0	0	0	0	0
f)FIIs	0	0	0	0	0	0	0	0	0
h)Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
i) Others (specify) Foreign Portfolio Investors (Corporate)	0	0	0	0	0	0	0	0	0
Sub-Total(B)(1):	0	0	0	0	0	0	0	0	0
(2) Non-Institutions									



a) Bodies Corporate									
i) Indian	0	0	0	0	0	0	0	0	0
ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals									
i) Individual Shareholders holding nominal share capital up to Rs. 1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual Shareholders holding nominal share capital in excess of Rs. 1 lakh	0	0	0	0	0	0	0	0	0
C) Others (specify)									
Trusts	0	0	0	0	0	0	0	0	0
Sub Total (B)(2):	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	40	0	0	0	0	0
C.Shares held by Custodian for GDR & ADRs	0	0	0	0	0	0	0	0	0
Grand.Total (A+B+C)	0	10000	10000	100	0	10000	100000	100	0



(ii) Shareholding of Promoters

SI No.	Shareholder's Name	Shareholding at the beginning of the year (as on incorporation date)			Cumulative Shareholding during the year			% Change in shareholding during the year
		No. of shares	% of total shares of the Company	% of Shares Pledged/encumbered to total shares	No. of shares	% of total Shares of the Company	% of Shares Pledged/encumbered to total shares	
1	Saili More	5000	50%	0	5000	50%	0	0
2.	Ashish Sakalkar	5000	50%	0	5000	50%	0	0

(iii) Change in Promoters' Shareholding (Please specify, if there is no change): NO CHANGE**(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs): NOT APPLICABLE****IV. INDEBTEDNESS**

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year i.e., 16.04.2019				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	0	0	0	0
Change in Indebtedness during the financial year				
- Addition	75,30,299	25,45,962	0	1,00,76,261
- Reduction				



Net Change	75,30,299	25,45,962	0	1,00,76,261
Indebtedness at the end of the financial year i.e., 31.03.2020				
i) Principal Amount	75,30,299	25,45,962	0	1,00,76,261
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	75,30,299	25,45,962	0	1,00,76,261

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and Manager: **NIL**

B. Remuneration to other directors:

SN.	Particulars of Remuneration	Name of Directors			Total Amount
		----	----	----	
1	Independent Directors	----	----	----	
	Fee for attending board committee meetings	----	----	----	
	Commission	----	----	----	
	Others, please specify	----	----	----	
	Total (1)	----	----	----	
2	Executive Directors	ASHISH SAKALKAR	MEDHA PRABHUDESAI	----	
	Remuneration	7,00,000	7,00,000	----	14,00,000
	Bonus	----	----	----	----
	Total (2)	7,00,000	7,00,000	----	14,00,000
3	Other Non-Executive Directors				
	Fee for attending board committee meetings				
	Commission				
	Others, please specify				



Total (3)					
Total (B)=(1+2+3)	----	----	----	----	----
Total Managerial Remuneration	----	----	----	----	----
Overall Ceiling as per the Act	N.A				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD: NIL

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES: NIL

